As ICIs have become an essential treatment modality in non-small cell lung cancer (NSCLC) treatment for those patients without EGFR or ALK mutations (3, 4), it becomes necessary to develop reliable methods of predicting and monitoring immune responses to these drugs (5, 6). This evidence concerns the gene ALK and non-small cell lung carcinoma.